eRapa

Phase 3Small molecule

RRapamycin Holdings, Inc. dba Emtora Biosciences

eRapa is one of 84 small molecule programs targeting Familial adenomatous polyposis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Adenomatous PolyposisActive, not recruiting

Prostate CancerActive, not recruiting

Bladder CancerActive, not recruiting

Familial Adenomatous PolyposisPhase 3

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

eRapa

RRapamycin Holdings, Inc. dba Emtora Biosciences

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Statin

Bristol-Myers Squibb

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—9

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

9 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 3Recruiting

Familial Adenomatous Polyposis

NCT06950385

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Recruiting·RRobert Svatek·Phase 2·NCT04375813·166 enrolled

Familial adenomatous polyposis1 trial

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Recruiting·RRapamycin Holdings Inc.·Phase 3·NCT06950385·168 enrolled

Prostate Cancer1 trial

Trial of eRapa in Prostate Cancer Patients

Completed·RRapamycin Holdings, Inc. dba Emtora Biosciences·Phase 1·NCT03618355·15 enrolled

Familial Adenomatous Polyposis (FAP)1 trial

Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis

Available·BBiodexa Pharmaceuticals··NCT07689942

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for eRapa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eRapa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eRapa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rapamycin Holdings, Inc. dba Emtora Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRapamycin Holdings, Inc. dba Emtora Biosciences

eRapa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Bladder Cancer1 trial

Familial adenomatous polyposis1 trial

Prostate Cancer1 trial

Familial Adenomatous Polyposis (FAP)1 trial

References

Drug Info

Quick Facts

Related News